MENU
+Compare
PHMMF
Stock ticker: OTC
AS OF
Jun 23 closing price
Price
$92.57
Change
-$1.24 (-1.32%)
Capitalization
1.68B

PHMMF stock forecast, quote, news & analysis

Pharma Mar SA is engaged in the research, development, production, and commercialization of bio-active principles of marine origin for application in oncology... Show more

PHMMF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
Interact to see
Advertisement
A.I.Advisor
a Summary for PHMMF with price predictions
Jul 25, 2025

PHMMF in upward trend: price expected to rise as it breaks its lower Bollinger Band on June 20, 2025

PHMMF may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 24 cases where PHMMF's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 22 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 22 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

The Momentum Indicator moved above the 0 level on July 08, 2025. You may want to consider a long position or call options on PHMMF as a result. In of 51 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for PHMMF just turned positive on July 23, 2025. Looking at past instances where PHMMF's MACD turned positive, the stock continued to rise in of 35 cases over the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

PHMMF moved below its 50-day moving average on July 08, 2025 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for PHMMF crossed bearishly below the 50-day moving average on July 08, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 11 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

The Aroon Indicator for PHMMF entered a downward trend on July 25, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.859) is normal, around the industry mean (18.053). P/E Ratio (69.558) is within average values for comparable stocks, (59.920). PHMMF's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.580). Dividend Yield (0.010) settles around the average of (0.044) among similar stocks. P/S Ratio (7.740) is also within normal values, averaging (280.104).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. PHMMF’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PHMMF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

A.I.Advisor
published Dividends

PHMMF paid dividends on April 30, 2021

Pharma Mar SA PHMMF Stock Dividends
А dividend of $0.60 per share was paid with a record date of April 30, 2021, and an ex-dividend date of April 28, 2021. Read more...
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Moderna (NASDAQ:MRNA), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Novavax (NASDAQ:NVAX), Sarepta Therapeutics (NASDAQ:SRPT), Nektar Therapeutics (NASDAQ:NKTR).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.57B. The market cap for tickers in the group ranges from 58 to 313.33B. NONOF holds the highest valuation in this group at 313.33B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was 8%. For the same Industry, the average monthly price growth was 17%, and the average quarterly price growth was 27%. CNSP experienced the highest price growth at 1,002%, while REPL experienced the biggest fall at -74%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 18%. For the same stocks of the Industry, the average monthly volume growth was -35% and the average quarterly volume growth was 85%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 84
Price Growth Rating: 55
SMR Rating: 92
Profit Risk Rating: 94
Seasonality Score: -3 (-100 ... +100)
View a ticker or compare two or three
PHMMF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
Avenida de los Reyes, 1
Phone
+34 918466000
Employees
487
Web
http://www.pharmamar.com